Docetaxel-d9 (Synonyms: DTX-d9, Taxotel-d9)

Docetaxel-d₉ is intended for use as an internal standard for the quantification of docetaxel by GC- or LC-MS. Docetaxel is a semisynthetic analog of paclitaxel that inhibits microtubule disassembly (IC₅₀ = 0.2 μM) and inhibits cell replication (IC₅₀ = 0.13 μM).¹ It has proven more effective than taxol in preventing the proliferation of cancer cells.^1,2 Docetaxel has potential applications in breast cancer and hormone-refractory prostate cancer.^3,4

1.Bissery, M.C., Guenard, D., Gueritte-Voegelein, F., et al.Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogueCancer Research514845-4852(1991) 2.Pazdur, R., Kudelka, A.P., Kavanagh, J.J., et al.The taxoids: Paclitaxel (Taxolr) and docetaxel (Taxoterer)Cancer Treatment Reviews19351-386(1993) 3.Mahon, K.L., Henshall, S.M., Sutherland, R.L., et al.Pathways of chemotherapy resistance in castration-resistant prostate cancerEndocrine-Related Cancer18R103-R123(2011) 4.Yao, X., Hosenpud, J., Chitambar, C.R., et al.A phase II study of concurrent docetaxel, epirubicin and cyclophospha-mide as a neoadjuvant chemotherapy regimen in patients with locally advanced breast cancerJournal of Cancer3145-151(2012)